Bedrijfstakpensioenfonds Voor DE Media PNO Purchases 5,500 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Bedrijfstakpensioenfonds Voor DE Media PNO raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,150 shares of the medical research company's stock after purchasing an additional 5,500 shares during the period. Thermo Fisher Scientific accounts for about 2.8% of Bedrijfstakpensioenfonds Voor DE Media PNO's portfolio, making the stock its 11th biggest position. Bedrijfstakpensioenfonds Voor DE Media PNO's holdings in Thermo Fisher Scientific were worth $21,069,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Northwest Financial Advisors purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. True Wealth Design LLC raised its holdings in shares of Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company's stock worth $29,000 after buying an additional 51 shares during the period. Pineridge Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $39,000. Cape Investment Advisory Inc. raised its holdings in shares of Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company's stock worth $40,000 after buying an additional 26 shares during the period. Finally, Raleigh Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company's stock worth $41,000 after buying an additional 27 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on TMO. Barclays increased their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an "equal weight" rating in a research note on Thursday. JPMorgan Chase & Co. raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research report on Thursday. Royal Bank of Canada raised their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $606.76.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael A. Boxer sold 14,566 shares of the company's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company's stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 over the last ninety days. Corporate insiders own 0.32% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO stock traded up $1.87 during trading on Friday, hitting $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company's 50-day moving average price is $573.60 and its two-hundred day moving average price is $530.14. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39. The stock has a market capitalization of $218.95 billion, a P/E ratio of 36.79, a PEG ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 21.54 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific's dividend payout ratio is 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.